Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report analysing the organ transplant industry.
Organ Transplant Immunosuppressive Markets reports that the number of organ transplants performed worldwide is approximately 70,000 annually. As medical science extends the life expectancy of patients with transplanted organs, demand continues to increase for safe, effective immunosuppressants to control transplant rejection.
Authors of the report note that improved surgical techniques and organ preservation, understanding of immunologic barriers, and the development of newer and more potent immunosuppressives have combined to improve survival of transplant patients and grafts.
The report shows that rejection remains the major barrier to long-term graft survival in patients. Organ transplantation therapy is highly dependent on the success of immunosuppressants to suppress the recipient’s immune responses to the foreign organ. Most transplant patients require lifelong immunosuppressive therapy to prevent rejection, except when human leukocyte antigen (HLA)-identical transplants are used.
The report is focused on immunosuppressants utilised in solid organ transplantation. It provides an in-depth look into the trends that have shaped today’s use of transplant immunosuppression regimens, and details the current and future global market.
Included in this report:
- Detailed statistics on Transplant Need, Organ Transplant Procedures, Costs, Patient Waiting Lists, and Patient Survival Rates
- Immunosupressive Current Market and Forecasts
- Breakouts of Immunosuppressive Drugs by Drug Type and by Organ Transplanted
- Regional Breakout of Immunosuppressive Sales (US, Europe, Asia/Pacific, Rest of World)
- Market Share of Immunosuppressive Market
- Review of Current Products and New Products in Development
- Profiles of Immunosuppressive Market Competitors
Organ Transplant Immunosuppressive Markets
Report Buyer product ID: KAL00109
Report Buyer category: Pharma & Healthcare
